1.52 USD
-0.03 (-1.94%)
1.53 USD
+0.01 (+0.66%)
We assign a fundamental rating of 3 out of 10 to CRBU. CRBU was compared to 525 industry peers in the Biotechnology industry. CRBU scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CRBU is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year CRBU has reported negative net income.
- In the past year CRBU has reported a negative cash flow from operations.
- In the past 5 years CRBU always reported negative net income.
- CRBU had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- CRBU has a Return On Assets of -80.58%. This is in the lower half of the industry: CRBU underperforms 68.38% of its industry peers.
- CRBU has a Return On Equity (-110.77%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -80.58% | ||
| ROE | -110.77% | ||
| ROIC | N/A |
ROA(3y)-32.6%
ROA(5y)-41.65%
ROE(3y)-39.9%
ROE(5y)-65.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- CRBU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- CRBU does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for CRBU has been increased compared to 1 year ago.
- Compared to 5 years ago, CRBU has more shares outstanding
- There is no outstanding debt for CRBU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -4.11, we must say that CRBU is in the distress zone and has some risk of bankruptcy.
- CRBU's Altman-Z score of -4.11 is in line compared to the rest of the industry. CRBU outperforms 42.86% of its industry peers.
- There is no outstanding debt for CRBU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.11 |
ROIC/WACCN/A
WACC8.88%
2.3 Liquidity
- A Current Ratio of 5.54 indicates that CRBU has no problem at all paying its short term obligations.
- CRBU has a Current ratio (5.54) which is in line with its industry peers.
- CRBU has a Quick Ratio of 5.54. This indicates that CRBU is financially healthy and has no problem in meeting its short term obligations.
- CRBU has a better Quick ratio (5.54) than 60.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.54 | ||
| Quick Ratio | 5.54 |
3. Growth
3.1 Past
- CRBU shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.03%.
- CRBU shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.00%.
- CRBU shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.54% yearly.
EPS 1Y (TTM)-3.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.05%
Revenue 1Y (TTM)-19%
Revenue growth 3Y1.35%
Revenue growth 5Y11.54%
Sales Q2Q%8.6%
3.2 Future
- Based on estimates for the next years, CRBU will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.70% on average per year.
- Based on estimates for the next years, CRBU will show a very strong growth in Revenue. The Revenue will grow by 61.30% on average per year.
EPS Next Y0.58%
EPS Next 2Y5.97%
EPS Next 3Y3.3%
EPS Next 5Y8.7%
Revenue Next Year-4.31%
Revenue Next 2Y-0.01%
Revenue Next 3Y4.23%
Revenue Next 5Y61.3%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- CRBU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year CRBU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.97%
EPS Next 3Y3.3%
5. Dividend
5.1 Amount
- No dividends for CRBU!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CARIBOU BIOSCIENCES INC / CRBU FAQ
Can you provide the ChartMill fundamental rating for CARIBOU BIOSCIENCES INC?
ChartMill assigns a fundamental rating of 3 / 10 to CRBU.
What is the valuation status for CRBU stock?
ChartMill assigns a valuation rating of 0 / 10 to CARIBOU BIOSCIENCES INC (CRBU). This can be considered as Overvalued.
Can you provide the profitability details for CARIBOU BIOSCIENCES INC?
CARIBOU BIOSCIENCES INC (CRBU) has a profitability rating of 0 / 10.
What is the earnings growth outlook for CARIBOU BIOSCIENCES INC?
The Earnings per Share (EPS) of CARIBOU BIOSCIENCES INC (CRBU) is expected to grow by 0.58% in the next year.